Tracleer and Questran drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Tracleer (bosentan) and Questran (cholestyramine). Common drug interactions include asthenia among females and agranulocytosis among males.

The phase IV clinical study analyzes what interactions people have when they take Tracleer and Questran. It is created by eHealthMe based on reports of 21 people who take the same drugs from the FDA, and is updated regularly.

What is Tracleer?

Tracleer has active ingredients of bosentan. It is often used in primary pulmonary hypertension. eHealthMe is studying from 55,125 Tracleer users. Check the latest studies of Tracleer.

What is Questran?

Questran has active ingredients of cholestyramine. It is often used in diarrhea. eHealthMe is studying from 4,490 Questran users. Check the latest studies of Questran.

On Aug, 01, 2026

21 people who take Tracleer and Questran together, and have interactions are studied.

Tracleer and Questran drug interactions.

What are the common drug interactions of Tracleer and Questran, by gender? *:

female:

Asthenia (weakness)
Blood bilirubin increased
Chest pain
Cachexia (loss of weight)
Colitis ischaemic (due to infection of intestine impaired blood supply to colon)
Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
Drug toxicity
Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
Hallucination (an experience involving the perception of something not present)
Pulmonary embolism (blockage of the main artery of the lung)

male:

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
Cardiac arrest
Cytolytic hepatitis (dissolution or destruction of a liver cell)
Hepatic congestion (liver congestion)
Lung disorder (lung disease)
Metabolic acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body)
Pulmonary embolism (blockage of the main artery of the lung)
Respiratory disorder (respiratory disease)

What are the common drug interactions of Tracleer and Questran, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Blood chloride decreased
Chest pain
Dehydration (dryness resulting from the removal of water)
Hypokalaemia (low potassium)
Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
Hypotension (abnormally low blood pressure)
Nausea (feeling of having an urge to vomit)
Pneumonia
Retching (strong involuntary effort to vomit)
Syncope (loss of consciousness with an inability to maintain postural tone)

50-59:

Abdominal pain
Ascites (accumulation of fluid in the abdominal cavity)
Autoimmune hepatitis
Disease progression
Hepatic cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue)
Hepatic steatosis (fatty liver disease)
Peripheral swelling
Pyrexia (fever)
Urinary tract infection
Varices oesophageal (enlarged and swollen veins at the bottom of the oesophagus, near the stomach)

60+:

Alanine aminotransferase increased
Aspartate aminotransferase increased
Chest pain
Headache (pain in head)
Pain in jaw
Anaemia (lack of blood)
Cardiac arrest
Colitis (inflammation of colon)
Drug ineffective
Drug toxicity

What are the existing conditions these people have? *

Pulmonary Hypertension (increase in blood pressure in the lung artery): 9 people, 42.86%
Pulmonary Hypertension Primary (increase in blood pressure in the lung artery with no cause): 3 people, 14.29%

* Approximation only. Some reports may have incomplete information.

Do you take Tracleer and Questran?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously